Scientific Program

Day 1

Keynote Session:

09:30-09:55

Mitsuji Yamashita

Shizuoka University, Japan

Title: Innovative and strategic materials against cancer: Preclinical researches on tumour accumulative novel sugar dendritic Gd-DTPA complex MRI contrast agents and IER5/Cdc25B targeted novel phospha sugar anti-tumour agents to innovate in cancer therapy

Biography:

Mitsuji Yamashita has completed his PhD at the age of 27 years from Nagoya University, Japan and postdoctoral studies from Toyota Science and Chemistry Research Institute, Japan and Iowa State University, USA. He was a visiting professor of University of Massachusetts, USA and a researcher of Oxford University, UK in 1994. He was promoted to be a professor of Shizuoka University, Japan in 1998 and retired at the age of 65 years old. He is now a professor emeritus of Shizuoka University, Japan. He has published more than 185 papers, patents, and books.

Abstract:

Innovative materials against tumour to decrease remarkably the number of persons died by cancer are desired eagerly. To innovate in the medical technologies, tumour accumulative sugar dendritic Gd-DTPA complex MRI contrast agent (DEN-OH) and IER5/Cdc25B targeted novel phospha sugar antitumour agents (TBMPP) were prepared and evaluated preclinically. These novel medicinal materials were revealed to exert excellent characteristics against tumour cells. DEN-OH was prepared by introduction of protected sugar dendritic parts to the ligand of diethylenetriamine pentaacetic acid (DTPA) and the successive complex formation with Gd (III) and hydrolysis. The prepared DEN-OH for MRI contrast agent with the less concentration (10% Gd concentration of Gd-DTPA complex) showed quite clearer images of quite early stage cancer. Phospha sugar derivatives were prepared by new synthetic pathway to construct the compound library. Deoxybromophospha sugar derivatives such as TBMPP (Tribromophospha sugar derivative) prepared from phospholene derivative were first found to exert quite strong and wide spectral antitumor activities by in vitro evaluation against various kinds of leukemia cells such as K562, U937, etc. cell lines as well as solid cancer cells. Mechanistic studies with TBMPP against leukemia cells by Western blotting showed that the phospha sugar enhanced the expression of IER5, suppressed the expression of Cdc25B against tumour cells selectively and specifically, and then induced apoptosis at the mitosis step of the tumour cell cycle. Invivo evaluation for TBMPP was successfully performed by using a nude mouse transplanted by K562 cells on the skin.

09:55-10:20

Larisa Klapshina

N. I. Lobachevsky State University of Nizhny Novgorod, Russia

Title: Novel series of cyano-aryl porphyrazines with benzyloxy and propargyl substituents in peripheral aryl fragments for specifically personalized medicine: Optical viscosity sensing and PDT treating

Biography:

Larisa Klapshina received her PhD from Razuvaev Institute of Organometallic Chemistry of Russian Academy of Sciences, IOMC RAS Nizhny Novgorod, Russia. Currently she is a senior researcher at IOOMC RAS and at the Laboratory of Optical Theranostics in Nizhny Novgorod State University. She and her group work in organic, organometallic synthesis and functional materials in bio-photonics and biomedicine. She is author of about 100 articles.

Abstract:

For a long time the idea of separated diagnostic and therapeutic approaches was predominant in the development of new drugs in medicine. However, recently a significant increase has been observed in the trend to create drugs which effectively combine diagnostic and therapeutic approaches. Such the drugs termed the agents of theranostics allow to determine the tumor localization in the body and to provide a therapeutic effect on it. Furthermore, in some cases theranostic agent allows to provide the real time monitoring of individual therapeutic response to the treatment procedure. Recently we reported on the preparation and studies of the photophysical properties of new fluorescent porphyrazine pigments which have been found to be an excellent platform for drugs with the unique combination of various biomedical functions: Bimodal (fluorescent/ MRI) diagnostic agents, sensitive optical sensors of intracellular viscosity and highly efficient photosensitizers in photodynamic therapy. Here we report the new series of aryl-cyano porphyrazine pigments containing n-donor oxygen atoms in the aromatic groups of peripheral frame of tetrapyrrol macrocycle. They demonstrate significantly improved photocytoxic properties and the potential for biomedical application as photosensitizers in PDT in comparison with previously reported aryl-cyano porphyrazine Pz1. Moreover, this series of tetrapyrrols the structural feature of which is the alternation of strongly electron withdrawing CN and Pi-donor aryl groups in the peripheral frame of macrocycle have been found to be novel fluorescent molecular rotor type dyes with the desirable feature of intense absorption and emission of red light that can be useful in vivo to enable deep tissue penetration in the tissue optical window. High efficacy of all the series as the fluorescent sensors of local viscosity in a wide viscosity range, had been demonstrated. Furthermore, we first proposed semi-empirical model describing photophysical behavior of novel porphyrazine series. The model was verified with fluorescence decay investigations for all the porphyrazine series, T.

10:20-10:45

Yue-Wei Guo

Shanghai Institute of Material Medica, Chinese Academy of Sciences, China

Title: Terpenenoids from the hainan marine invertebretes: Structure, absolute stereochemistry and biological activities

Biography:

Yue-Wei Guo is currently a professor at Shanghai Institute of Material Medica, Chinese Academy of Sciences, China. He received his PhD degree from Naples University, Italy in 1997. He was then a postdoctoral researcher in Istituto di chimica Biomolecolare-CNR, Italy from 1997 to 1999 and visiting professor in Hokaido University, Japan from 1999 to 2000. His research interests mainly focus on the chemistry, chemoecology and bioactivity of the secondary metabolites from marine benthic invertebrates (molluscs, sponges and coelenterates etc.) and flora. He has authored over 400 original research papers and reviews in peer-reviewed and SCI-indexed journals.

Abstract:

Marine benthic invertebretes (Sponges and soft corals etc.) are widely distributed in the coral reefs of the world oceans. Of them, the animals belonging to the genus Sarcophyton (phylum Cnidaria, class Anthozoa, subclass Octocorallia, order Alcyonaceae, family Alcyoniidae) are very prolific and are the intense research subjects for marine natural product chemists. Literature checking revealed that Sarcophyton animals can produce different structural classes of secondary metabolites exhibiting various interesting biological activities ranging from antifouling, anti-inflammatory to cytotoxic activities. Among the metabolites reported, cembrane-type diterpenes are the most frequently encountered. Moreover, biscembranoids, characterized by the complex and highly oxygeneted macrocyclic frameworks, which are formally synthesized from two different cembranoid units via a probable [4+2] Diels-Alder cyclic addition, are unique and typical natural products from soft corals of the genera Sarcophyton. Due to the flexible nature of the macrocycles accompanying with the highly diverse substitution patterns, it has been being a challenging task for their structural, in particular, the absolute stereochemistry, determination by natural product chemists. In this presentation, I’ll present the latest chemical studies and promising bioactivity results on the sarcophyton corals and sponge spongia officinalis collected from South China Sea. All work has been performed in close collaboration with marine biologists and with pharmacologists.

10:45-11:10

Mahendra Nath Roy

University of North Bengal, India

Title: Study to explore subsistence of host-guest inclusion complexes of significant drug molecules with alpha and beta-cyclodextrins and their applications in pharmaceutical science

Biography:

Mahendra Nath Roy is a senior professor in the Department of Chemistry and Chairman of Sports Board, University of North Bengal, India. His research interests are in the areas of host-guest inclusion complexes and solution thermodynamics. He has supervised 38 PhDs reviewed 36 PhD theses and many referred research papers and authored over 302 research articles and books in chemistry. He has received the award of one time grant under basic scientific research from University Grants Commission, “Prof. Suresh C. Ameta Award” from ICS, “Bronze Medal 2017” from CRSI and Shiksha Ratna Award from the government of West Bengal, India.

Abstract:

Host-guest inclusion of two drugs, phenylephrine hydrochloride and synephrine with α and β-cyclodextrins and their applications in biological Sciences have been investigated by physicochemical and microbiological approach. Phenylephrine hydrochloride (PEH) is a selective α1-adrenergic receptor agonist of the phenethylamine class used primarily in cold and flu conditions as an antipyretic, analgesic drug to relief pain. Alkaloid synephrine (SNP) was first extracted as a natural product from the leaves of various citrus trees is used as bronchial muscle reluctant, increases blood pressure in the patients suffering from low blood pressure. Formation of Host Guest Inclusion complexes of PEH and SNP with the CDs have increased the activities of the drugs concerned and controlled the dose for regulatory dischargement i.e. the drugs can be released as per requirement of the patient to avoid the side effects which have been explored in this research paper.

11:20-11:45

Sjaak Vink

TheSocialMedwork, The Netherlands

Title: Accelerating global access to health innovations

Biography:

Sjaak Vink has always aimed to create a more equal and fair healthcare system that gives everyone, everywhere the access they need. After a successful career in advertising, he set out to dedicate his time towards social good. He has found TheSocialMedwork in 2014 with the sole mission to help patients all over the world to get access to the newest treatments not approved in their home countries.

Abstract:

Healthcare access is a worldwide challenge. Every day, patients from all over the world are denied access to elsewhere approved health innovations for arbitrary reasons. I have also been there myself. I experienced personal hardships friends who passed away before ever accessing the medicines they needed. I was determined to find a way to undo the injustices of medicines access on a global scale and to accelerate this process to patients all over the world. The creation of TheSocialMedwork is a timely and critical one, with only 11 years separating us from the 2030 health targets of the United Nations. It is our responsibility and duty to eradicate this challenge as soon as possible. Our aim is to keep pushing for a change in the access to healthcare landscape every single day. We have now safely delivered over 5,500 latest innovative medicines to over 75 countries, years before the official availability in these countries. Under the named patient import basis, TheSocialMedwork is safely and legally delivering medicines to all over the world. TheSocialMedwork’s end goal is global health access for everyone regardless of their financial situation. This is why we are working towards crowd funding, blockchain transparency, pricing algorithms and conditional reimbursement pilots. In the future we aim to further work together with pharma companies, patient organizations and healthcare professionals to provide patients with the latest and most innovative treatments at their fingertips the second they become approved around the world. Let’s make this world work for everyone!

11:45-12:10

David McClintock

University of Michigan, USA

Title: Deploying digital pathology to enable artificial intelligence: Understanding fundamental requirements, barriers and opportunities in digital pathology

Biography:

David McClintock is an associate CMIO of Michigan Medicine (Pathology Informatics), Director of Digital Pathology, Associate Director of Pathology Informatics and associate professor at the University of Michigan, USA. His primary clinical interests comprise operational pathology and clinical laboratory informatics including workflow analysis, Laboratory Information System (LIS) optimization, and improved integration of pathology and clinical laboratory data within the EHR and clinical research data warehouses.

Abstract:

For many, the promises of digital pathology (DP) to streamline workflows, improve laboratory quality and to improve patient care are not readily apparent, especially when faced with the high costs of deploying DP. Calculating return on investment from introducing yet another layer of complexity and handoffs in an already complicated surgical pathology process can be riddled with inaccuracies and assumptions, such as major laboratory personnel (FTE) savings, decreases in turn-around time, and increased potential business through digital consults. Recently, the application of machine learning and artificial intelligence (AI) to whole slides images has emerged as a primary use case for the adoption of large-scale digital pathology efforts. With AI, multiple use cases now exists, that have the potential to transform the way pathology is practiced, both within the anatomic pathology laboratory and the pathologist sign out workspaces. This talk will describe how, by understanding the fundamental requirements, barriers to adoption, and opportunities for future growth related to digital pathology, one will be able to successfully determine how to deploy this new technology to its greatest ability.

12:10-12:35

Ulysses G J Balis

University of Michigan, USA

Title: Use of hand-crafted spatial classifiers as a pre-processing stage to enhance performance of machine learning-based analysis of histopathological subject matter

Biography:

Ulysses G J Balis completed his MD training at the University of South Florida, USA his residency training in Anatomic and Clinical Pathology at the University of Utah, and separate, sequential Postdoctoral fellowships in Tissue Engineering and Bioinformatics at the Center for Engineering in Medicine at Harvard Medical School. He currently serves as the Director of the Division of Pathology Informatics at the University of Michigan, USA.

Abstract:

The application of convolutional neural network (CNN) based analysis to histopathological subject matter has already demonstrated significant utility for both general image classification tasks, as well as for implementation of unsupervised partitioning of datasets into multiple appropriate diagnostic subclasses. This approach is generally successful in settings where sufficient case numbers are available. Use of CNNs is attractive in that it can help to avoid the need for laborious generation of ground truth maps, as performed by subject matter experts. However, CNNs are limited in that their convergence on a generalizable solution often requires the availability of 100’s, if not 1000’s, of training set images. This lowers the utility of this approach for certain classes of histopathological subject matter, where large cohorts of cases and images are unavailable. To address this limitation, we present the use of an additional preprocessing stage, with the use of hand-crafted feature classifiers, prior to the application of conventional CNN-based methodologies. This multi-stage approach has been applied to a number of histology classification use-cases, with preliminary results demonstrating that in many cases, the requirement for having hundreds or thousands of images can be significantly reduced, to instead only requiring a few representational images. A number of use cases will be presented, demonstrating consistently high ROC performance, even in the setting of having small numbers of initial cohort images in the training set.

12:35-13:00

Andrea M P Romani

Case Western Reserve University, USA

Title: Cellular magnesium as a regulator of glucose homeostasis and insulin- mediated signaling and cellular metabolism

Biography:

Andrea M P Romani, obtained his medical degree from the University of Siena, Italy and his PhD from the University of Turin, Italy. Upon completing his postdoctoral studies under Dr. Scarpa, he joined the faculty in the Department of Physiology and Biophysics, Case Western Reserve University, where he is currently the associate professor. He has published over 90 peer review articles in high profile journals together with numerous invited reviews and book chapters on the role of mammalian magnesium homeostasis in health and disease.

Abstract:

The last thirty years have registered a progressive and dramatic increase in the incidence of obesity and type 2 diabetes mellitus world-wide. Metabolic Syndrome, one of the most commonly conditions associated with obesity and insulin resistance, has also increased considerably. The latest releases from the WHO estimate that approximately 1 billion people worldwide are obese, and more than 500 million are diabetic or pre- diabetic. Interestingly, increasing evidence suggest that our current western diet is hypercaloric but hyponutritive, as it is lacking essential micronutrients and minerals. Our laboratory has focused on the possible role of reduced cellular magnesium levels in the dysregulation of cellular and systemic glucose homeostasis. Experimental data obtained in animal and cellular models, including cells of human origin support the conclusion that cellular magnesium regulates transmembrane glucose transport as well as its utilization, and neosynthesis in gluconeogenic tissues, by modulating the activity of specific cellular enzymes and insulin-mediated signaling. Regardless of the tissue considered, decreased cellular and serum magnesium levels impact the proper operation of Glut 4, and Glut 2 transporters, thus limiting the ability of tissues like heart, muscles, liver, and possibly beta-islets, to effectively transport glucose into the cell to support glycolysis, ATP production, and ultimately storage as glycogen. As a consequence, gluconeo-genesis becomes erroneously activated, further enhancing the circulating levels of glucose and resulting in the dysregulation of fatty acids, cholesterol, and protein degradation, to support gluconeogenic activity through increased cortisol production and insulin resistance. Also, decreased cellular magnesium levels appear to contribute directly to increased basal inflammation within tissues, further impairing insulin responsiveness and systemic metabolic homeostasis. Altogether, our results argue for the necessity to better understand the role that micronutrients play in modulating both organ- specific and systemic metabolism and inflammation, to ultimately identifying more effective therapeutic and dietary approaches.

14:00-14:45

David McClintock, Ulysses G J Balis, Jerome Cheng

University of Michigan, USA

Title: A generalizable model for histopathological spatial feature segmentation and classification by use of the SIVQ/VIPR algorithm as a spatial pre-processing stage

Biography:

David McClintock is an associate CMIO of Michigan Medicine (Pathology Informatics). Director of Digital Pathology. Ulysses G J Balis currently serves as the Director of the Division of Pathology Informatics at the University of Michigan, USA. Jerome Cheng is a clinical assistant professor of Pathology in the Division of Pathology Informatics, in the Department of Pathology at University of Michigan, USA.

Abstract:

The generation of ground truth maps from digital whole slide image subject matter remains a labour-intensive and technically challenging task, with the net effect being that the curation of large libraries of consistently and accurately tagged features remains a daunting prospect for most histologybased machine vision research teams. To address this need, we have developed separate assisted and autonomous image segmentation computational pipelines, which both exhibit the property of converging on a highly generalizable classifier with a high area under the curve (AUC) solution, utilizing far fewer training image set tiles than typically required for deep learning schema. Initial histology feature segmentation and classification efforts with these tools have demonstrated compelling sensitivity and specificity, when compared against pixel-level ground truth maps, as generated by a panel of subject matter experts. Typical AUC values exceed 0.98 and the use of GPU-based computational clusters allows for segmentation activities to be carried out in real time, facilitating the discovery process. Interactive application demonstrations will be available as a component of the showcasing of this abstract.

14:45-15:30

Milenko Tanasijevic

Brigham and Womens Hospital, USA

Title: Strategic approach to building an advanced laboratory diagnostics program: The Brigham and Womens Hospital experience

Biography:

Milenko Tanasijevic is the Vice Chair for Clinical Pathology and Quality of the Pathology Department of the Brigham and Women's Hospital (BWH), the Director of the BWH Clinical Laboratories and an associate professor of Pathology at Harvard Medical School. He has co-founded Cell Imaging Systems Inc. and co-invented the technology that served as the basis for building the world’s first hematology instrument that integrates digital morphology, cell counting and classification into a single instrument.

Abstract:

Introduction of advanced diagnostics modalities has become an imperative for many hospital-based laboratories in the era of precision medicine. Yet, building a robust advanced laboratory diagnostics program poses significant challenges from the perspective of ensuring adequate human resources, access to technology and appropriate space. In this workshop, I will share our experience with strategic planning and implementation of key laboratory diagnostic initiatives such as advanced molecular diagnostics, histocompatibility, LC/MS, molecular microbiology and total laboratory automation. I will describe several frameworks for competitive positioning for modern diagnostic laboratories and describe some of the key factors for their ongoing success and sustainability. Finally, I will go over some important financial and regulatory challenges confronting clinical pathology programs.

15:30-16:15

Jerome Cheng

University of Michigan, USA

Title: Deep learning applications in the field of pathology

Biography:

Jerome Cheng is a clinical assistant professor of Pathology in the Division of Pathology Informatics, in the Department of Pathology at University of Michigan, USA. He had his residency training in Anatomic and Clinical Pathology at Suny Health Science Center in Brooklyn, New York and fellowship in Pathology Informatics at University of Michigan. He is board certified in AP/CP and Clinical Informatics.

Abstract:

In recent years, convolutional neural networks (CNN) have revolutionized the field of computer aided digital image analysis due to their accuracy in classifying and recognizing objects /patterns from different subject matters, including histopathological images. Aside from object classification, CNN is also useful for object detection/tracking and semantic segmentation. There is a lot of potential for deep learning to change and improve the practice of pathology due to the highly visual nature of the field, especially in tasks that pathologists find boring and tedious such as finding mitosis and counting cells. Other example applications of CNN in pathology include classification of lesions (e.g. benign vs. malignant), cancer localization, nuclei identification, and segmentation of regions of interests in an image. In the image below, a CNN model based on U-Net, together with a ground truth map, was able to accurately highlight regions of glomeruli in a kidney section. Running CNN experiments used to require a significant amount of programming expertise. Fortunately, open-source tools that need minimal or no programming knowledge such as Tensorflow and Orange (Biolab) are now available, making deep learning accessible to a wider audience, including pathologists.

5:00-5:30

Bahman Ebrahimi Saatloo

University of Urmia, Iran

Title: Synthesis of novel spiro pyrazolo-1,4-dihydropiridine via one-pot four-component reaction

Biography:

Bahman Ebrahimi Saatloo was born in Urmia (Iran) in 1979. He received his B.Sc in Applied Chemistry (2007) from the Urmia University. He will receive his Ph.D. degree in Organic Chemistry from the Urmia University (Iran) in 2017 after completing his research in the Study of Synthesis of Polyazadodecahedrone and Synthesis of Spirooxindole Compounds of 1,2,3,4- Tetrahydroqunoline by Base, Acid and Nano Catalysts under the guidance of Professor Mohammad Mehdi baradarani. His current research interest focuses on the synthesis of Spirooxindole and supramolecular in heterocyclic for organic synthesis.

Abstract:

Green synthesis of spiropyrazolo-1,4-dihydropyridine has been reported via one-pot four-component reaction in EtOH/H₂O (1:9) in the presence of p-TSA as a catalyst.

Spirooxindoles are classified as an important structural motif due to their distribution in diverse natural products, biologically and pharmaceutical activities such as the influenza virus [1], as inhibitors of the dengue virus and anti-cancer agents [2]. Therefore, we conducted a series of examination the chemistry of 5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolone-1,2-dione, in which the reactivity of the ketone carbonyl group of the 2-keto-amide unit was utilized. Thus, we were able to construct various spiro [3,3’-oxindoles] via three and four component combination [3]. Amongst, Spiropyrazole-1,4-dihydropyridine moieties have shown important biological and medicinal activities.

As a part of our ongoing interest in this context, we reported a simple and facile synthesis of a new type of spiropyrazolo-1,4-dihydropyridines (5) in the presence of p-TSA as a catalyst (scheme 1) from starting materials phenyl hydrazine hydrochloride derivatives (3), 3-aminobut-2-enenitrile (2), 3-oxo-3-phenyl propanenitrile (4) and 5,6-dihydro-1H-pyrrolo[3,2,1-ij]quinolone 1,2(4H)-dione (1) in environmentally friendly solvent, EtOH/H₂O.

Oral Session 1:

Clinical and Hospital Pharmacy | Drug Discovery and Development

Chair

Mitsuji Yamashita

Shizuoka University, Japan

16:25-16:45

Sofia Konstantinidou

National and Kapodistrian University of Athens, Greece

Title: Biosimilars: Current market and role in oncology care

Biography:

Sofia Konstantinidou is currently a PhD student at the Medical School, National and Kapodistrian Uninersity of Athens. She is a recipient of an Onassis Foundation Scholarship (G ZO 011-1/2018-2019) in Clinical Pharmacology-Oncology. She has participated in various conferences worldwide. She has published five articles in peer reviewed journals and one book chapter.

Abstract:

Biological products contain active substances coming from living cells and are usually large, complex proteins. They are used to treat many diseases such as cancer, rheumatoid arthritis, anaemia, renal failure and autoimmune diseases. However, due to their high cost, patient access is restricted, thus biosimilars came to the market. A biosimilar is defined by the United States Food and Drug Administration (FDA) as ‘biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product in terms of safety, purity and potency1’. They increase treatment options, decrease healthcare costs and improve patients’ access to very expensive therapies. Studies have proven that biosimilars offer significant cost savings to governments, which are greatly needed in the healthcare sectors. Only minor differences are acceptable between biologics and their respective biosimilars. Currently, there are few biosimilars approved for cancer treatment, but as the patents of many biologics are expiring, many more are coming to the market. These include rituximab, bevacizumab, trastuzumab, marketed for indications such as lymphomas, leukaemia, lung or breast cancer. Erythropoiesis-Stimulating agents (ESAs) are widely used for chemotherapy-induced anaemia2 and filgrastims for neutropenia respectively. Progression-free survival (PFS) and overall survival (OS) are usually used to measure the efficacy of biosimilars used in oncology3. The aim of this study is to provide a brief review of biosimilars, their perspectives in medical oncology and the current status of some clinical trials.

12:45-1:15

Miroslaw Kwiatkowski

AGH University of Science and Technology, Poland

Title: The numerical analysis of the adsorption process on BASOSIV M050 metal-organic frameworks material

Biography:

Miroslaw Kwiatkowski in 2004 obtained PhD degree at the AGH University of Science and Technology in Krakow (Poland). His published work includes more than 45 papers in reputable international journals and 80 conference proceedings. Miroslaw Kwiatkowski is the editor in chief of The International Journal of System Modeling and Simulation (United Arab Emirates), an associate editor of Micro & Nano Letters Journal (United Kingdom) and a member of the many editorial board of internationals journals.

Abstract:

Adsorption processes are among the widespread applications of Metal-Organic Frameworks (MOFs), which found employment in removal of harmful substances such as heavy metals from liquid and gaseous streams, storage and sequestration of gases such as carbon dioxide, methane and hydrogen as well as in separation and purification of gases products, catalytic processes and others. The performance and applicability of MOFs in mentioned processes among others depend on the high specific surface area and adsorption capacity. In this work adsorption properties of CO₂ and CH₄ on Basosiv M050 sample were determined by a volumetric method. The adsorbed volume values with respect to relative pressure were obtained for all of the gases. The nitrogen adsorption isotherms were studied at 77 K, and CO₂ and CH₄ isotherms were studied at 273 K. The BET and Langmuir surface areas of the samples were determined using N₂ adsorption isotherms. Adsorption capacities for CO₂ and CH₄ are also calculated from their isotherm analysis. Additionally, the new numerical method with the unique fast multivariant identification procedure was employed for the analysis of the adsorption process on a specific type of a MOF sample. The proposed tools permit the gathering of a broader spectrum of information on the analysed structure of MOFs materials and the adsorption processes taking place on their surface as compared with the others methods. Additionally the proposed method with unique numerical procedure can be a good starting point for the development of more advanced tools.

16:45-17:05

Ilyes Safir

University of Geneva, Switzerland

Title: Synthesis and structure formation in dilute aqueous solution of a chitosan-DNA hybrid

Biography:

Ilyes Safir has completed his PhD at the age of 33 years from Geneva University. Ilyes Safir is having international experience of performing research in materials science, nanosurface, nanotechnology, analytical chemistry. Skilled in preparing accurate nano-layers of thin polymer films, analysis with Atomic Force Microscope (AFM). Performed novel bio-nanostructured micelles/vesicles for drug delivery system.

Abstract:

Combination of straight biochemical and organic routes to graft nucleotide sequences to a chitosan backbone. The resulting chitosan-g-ssDNA hybrid self-assembles into submicrometer size structures in dilute aqueous solution as assessed by atomic force and electron microscopy imaging. The hypothesis of self-assembly driven by chemical incompatibility between the amphiphilic chitosan and nucleic acid grafts is supported further by stability of the self-assembly against ionic strength and pH variations.

17:05-17:25

Amit Verma

Sikkim Government College, India

Title: Development of natural high value nutritional formulations

Biography:

Abstract:

Nitrogen containing heterocycles with an oxygen atom are considered as an important class of compounds in medicinal chemistry because of their diversified biological applications. The exploitation of a simple molecule with different functionalities for the synthesis of heterocycles is a worthwhile contribution in the chemistry of heterocycles. Isoxazole is a five membered heterocyclic compoundcontaining oxygen and nitrogen atoms in the 1,2 positions, its partially saturated analogs are called isoxazolines and completely saturated analog is isoxazolidine.

17:05-17:25

Amit Verma

TRC Mahavidyalaya, India

Title: Development of natural high value nutritional formulations

Biography:

Amit Verma has graduated in Pharmacy (2004) from UP Technical University, Lucknow and completed his MPharm (2006) from UPTU, Lucknow, India. He got trained in CDRI, Lucknow for one year during his Master’s program. He then joined as a lecturer in NIE College, Lucknow, India. Before starting his PhD studies at The MS University, he was working with Jubilant Chemsys Ltd. as a research associate. He did his PostDoc from Freie University, Berlin.

Abstract:

The present study is focused for the development of nutritional formulations from Moringa leaf and other traditional food regularly used in India. The study is also focused to understand the food habits and actual requirements of different societies with different geographical region. Initially Moringa leaves have been taken for the fermentation process to evaluate the value of phytates in processed products. Different procedures have been adapted for processing and fermentation of leaves. Along with some already processed food has been evaluated for phytates level. Viz. fresh wheat dough and fresh roties (Indian Bread) and marketed breads has been evaluated for the presence of phytates level. Similarly some more Indian bread made up of fresh dough of maize, barley, qunoa, bajara and jwar (Indian Millets) has been evaluated for phytates levels. The study concluded that there is different type of processing of food which is responsible for the breakdown of phytates (Phytic acid polymer). The more the phytates level in food the less will be its nutritional value but on the other hand as phytates are high in food they do chelation of many toxic compounds and minerals which may trigger mutation in cells and may lead for the development of cancer.

3:45-4:15

Ahmed Abdelrahman Daoud

Tanta University, Egypt

Title: Is there relationship between Toxoplasma gondii IgG seropositivity and idiopathic Parkinsonism and does it have correlation with cortisol blood level?

Biography:

Ahmed Abdelrahman Daoud has completed his PhD in Medical parasitology at the faculty of medicine Tanta University 1980 and another PhD in Microbiology and Immunology in 1992 at Cairo Military Medical Academy.

Abstract:

Background: Some researches linked between latent Toxoplasmosis and neurological diseases, now the main interest is the propable relation between toxoplasmosis and neurological diseasesas epilepsy and Parkinsonism.

Aim: To detect the incidence of Toxoplasma gondii infection in patients idiopathic Parkinsonism and correlate it to their blood level of cortisol. Materials and Methods: This study was conducted on 30 idiopathic Parkinson's Patients, 30 psychiatric Patients, 30 apparently healthy individuals. All subjects were submitted to a questionnaire, detection of ant-Toxoplasma IgM, anti-Toxoplasma IgG and cortisol level by ELISA. Results: of the 90 cases; 41.11% and 1.11% were positive for ant-Toxoplasma IgM and IgG, respectively. The percentage of positive anti-Toxoplasma IgG cases was in healthy group (46.67%.) followed by Parkinsonism group (43.3%). Mean cortisol level higher in Pakinson's group than other groups but still within normal levels. Contact to cats, drinking unfiltered water and consuming unwashed raw vegetables were significantly higher in Toxoplsma IgG seropositive Parkinson's patients. Highest anti-Toxoplasma IgG positive casaes in Parkinson's group were detected in stage 3 of the disease .

Conclusion: A high Toxoplasma seropositivity in association with Parkinsonim. Toxoplasma gondii oocyst may be was the most propable main mode of transmission of Toxoplasma gondii in idiopathic Parkinson's patients. Toxoplasma gondii may worsen idiopathic Parkinsonism. Cortisol level was higher in Parkinson's patients, still it showed no significant relationship with Toxoplasma gondii seropositivity.

3:45-4:15

Kafa Khalaf Hammud

Ministry of Science & Technology, Iraq

Title: Pharmaceutical Chemistry in Iraq. recent research topics and drug industry

Biography:

Kafa Khalaf Hammud has completed her BSC, MSC, and PhD from Department of Chemistry, College of Science, Baghdad University, Iraq. She works at Directorate of Materials Research, Ministry of Science & Technology. She has published several scientific articles and has been serving as an editorial board member. Her main concern related to chemistry subjects such as synthesis, characterization and application.

Abstract:

This paper gave a mini review about pharmaceutical chemistry that started from lab experiments and end at publication stage but not at industry stage. There are many scientific paper that deal with new organic or organometallic compounds with good biological activities. These compounds are differing in their structures and methods of preparation beside the prior biological activities. The biological applications are mostly limited as antibacterial or antifungal agents at agar plates and may be solely increased to mice tests. These preparation and biological steps were dependant on the presence of functional groups or heteroatoms. So, Iraqi researchers as students or supervisors synthesized and characterized a large number of derivatives with no happy ending as a drug or treatment. This problem is present in medicinal herbs plant in Iraq. Many research papers about herbal extracts end at bacterial or fungal tests and may moved another step with cancer cell line then nothing more. In Iraq, there are the state company for drugs industry in Samarra (SDI) and other state in Nineveh (NDI). Both states are authorized for production of specific drugs such as antibiotics but not for new synthesized compounds might be a promising therapy. The Iraqi private drugs companies are limited in their choices and do not support such issue. For this case, I do think that solutions for this issue are related to main drug and disease relationship. In another words, we want a drug to treat a disease and industry need scientific documentations describes all pharmaceutical requirements and solution begins by supporting known companies searching of truth in facilitated labs.

5:00-5:30

Bahman Ebrahimi Saatloo

University of Urmia, Iran

Title: Synthesis of novel spiro pyrazolo-1,4-dihydropiridine via one-pot four-component reaction

Biography:

Bahman Ebrahimi Saatloo was born in Urmia (Iran) in 1979. He received his B.Sc in Applied Chemistry (2007) from the Urmia University. He will receive his Ph.D degree in Organic Chemistry from the Urmia University (Iran) in 2017 after completing his research in the Study of Synthesis of Polyazadodecahedrone and Synthesis of Spirooxindole Compounds of 1,2,3,4- Tetrahydroqunoline by Base, Acid and Nano Catalysts under the guidance of Professor Mohammad Mehdi baradarani. His current research interest focuses on the synthesis of Spirooxindole and supramolecular in heterocyclic for organic synthesis.

Abstract:

Green synthesis of spiropyrazolo-1,4-dihydropyridine has been reported via one-pot four-component reaction in EtOH/H₂O (1:9) in the presence of p-TSA as a catalyst. Spirooxindoles are classified as an important structural motif due to their distribution in diverse natural products, biologically and pharmaceutical activities such as the influenza virus, as inhibitors of the dengue virus and anti-cancer agents. Therefore, we conducted a series of examination the chemistry of 5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolone-1,2-dione, in which the reactivity of the ketone carbonyl group of the 2-keto-amide unit was utilized. Thus, we were able to construct various spiro [3,3’-oxindoles] via three and four component combination. Amongst, Spiropyrazole-1,4-dihydropyridine moieties have shown important biological and medicinal activities. As a part of our ongoing interest in this context, we reported a simple and facile synthesis of a new type of spiropyrazolo-1,4-dihydropyridines (5) in the presence of p-TSA as a catalyst from starting materials phenyl hydrazine hydrochloride derivatives (3), 3-aminobut-2-enenitrile (2), 3-oxo-3-phenyl propanenitrile (4) and 5,6-dihydro-1H-pyrrolo[3,2,1-ij]quinolone 1,2(4H)-dione (1) in environmentally friendly solvent, EtOH/H₂O.

Oral Session 2:

General Pathology | Digital Pathology | Clinical Pathology

Chair

Ulysses G J Balis

University of Michigan, USA

Dean Rakic

Blockchain Strategist, Germany

Title: Advancing digital pathology datafication with blockchain based technology

Biography:

Dean Rakic is a Blockchain Strategist & IoT expert. He accompanies customers of Novatec Consulting, Germany in the process of digitizing their processes. He has many years of experience in architecture for the processing of large amounts of data, especially in the medical environment.

Abstract:

With its principle of non-centralized data collection and non-central database, but sharing and distributing data across networks by credentialed users with the possibility to add and at the same time avoiding data alteration, Blockchain becomes a player in the digital healthcare. From the early buzz on healthcare, it has become lately a promising technology that is able to satisfy digital healthcare interoperability. Given the review of more studies in the Biobanks creation process and the classification of biosamples data, most stakeholders note possible obstacles in the digitization process such: data collection, who handles the data, sharing principle and data owning. At this point the new, common digital form denominator shall be introduced – Datafication. This process represents- collecting and analyzing acguizied bio data, deploying derived intelligence, generate and improve immaculate client experience, products, processes and operations, together with interoperability gives an answer to question: who owns all the data, giving people ownership of their personal data through blockchain, datafication based on blockchain, adopting data interoperability inside the flow of the biobanks creation process with notes of fine refinement and preparation for the end users. Such data are also verified and secured and no alteration of themselves is possible inside the interoperable block-chained cycle. Blockchain-based technologies will become the foundation for digital innovation in digital pathology. A unique combination of artificial intelligence, smart contracts and the blockchain will become the nervous system of the future biobank modelling, helping us live longer and healthier lives.

Sergey Biniaminov

HS Analysis GmbH, Germany

Title: Opportunities and risks of AI integration in daily routine in pathology today

Biography:

Sergey Biniaminov graduated with a diploma in Economics and Political Science at Karlsruhe Institute of Technology (KIT) and now he is managing shareholder and data scientist at HS Analysis GmbH, based in Karlsruhe. He is an expert in creating deep learning models and his passion is to understand the AI processes and integrate them into daily routine in pathology.

Abstract:

For diagnostic purposes, it’s important that microscopy images are not just images, diagnosis reports are not just unstructured information, and molecular data are not just separated from results of image analysis. Doctors and pathologists would be supported best, if suspicious or malicious structures of tissue samples are identified at the early stages. In that case the doctors be able to apply their expert knowledge more efficiently and to focus on the illness itself. This is exactly, what the HS Analysis GmbH does, when it comes to automated image analysis, structure reports and bring them with knowledge from molecular data. HS Analysis is working closely with different partners together, when digitization, digitalization and automation in pathology is going

to be a part of daily routine for pathologists. With the help of modern AI and Deep Learning supported methods, Sergey Biniaminov, CEO of HS Analysis, believes to seriously inspire diagnosis and research areas such as the early detection and therapy of cancer.

Bethelehem Nigussie

International Clinical Laboratories, Ethiopia

Title: A retrospective study of odontogenic tumors, cysts and maxillofacial bone tumors at Tikur Anbesa Hospital, Pathology Department, a 5 year experience

Biography:

Bethelehem Nigussie has completed her medical degree at the age of 24 from Addis Ababa University, College of Health Science, Ethiopia. After serving 2 years as a general practitioner in rural part of Ethiopia, she then joined Pathology Department and completed her postgraduate study at the same institution with Honors in 2018.

Abstract:

Introduction: This was a descriptive retrospective study done to analyze, compare and contrast the demographic, clinical and pathological data of odontogenic tumors, cysts and maxillofacial bone tumors seen at Tikur Anbesa Hospital, Pathology department from Sept.2013-Oct.2018. These were analyzed for age, gender, site of tumor as well as histopathologic type using the 2017 World Health Organization classification system. From a total of 132 cases reviewed, only 107 were having complete records suitable for the study. 59 of the study subjects were males while remaining 48 were female. 60(56.1%) of cases were benign, 16 were malignant and the rest 31 were non neoplastic. From the nonneoplastic cases,(87%) of the cases were odontogenic cysts most commonly occurring on maxilla (63%). The commonest benign odontogenic tumor was ameloblastoma (25%) with mean age of occurrence being 28.8 years and M: F ratio of 1.14:1. Majority occurred on the mandible 14(93.3%). Ossifying fibroma (20%) was the 2nd commonest benign lesion. 8 cases (50%) from the total malignant lesions were of osteosarcoma and primary intraosseous squamous cell carcinoma.

Conclusion: Odontogenic tumors, cysts and maxillofacial bone lesions show a definite geographic variation. In our study, ameloblastomas were the most frequent odontogenic tumor similar to other African studies but with a slightly younger age of presentation followed by benign fibroosseous lesions which was in contrary to most literatures.

Ali Ziaie Kia

Islamic Azad University, Iran

Title: Experimental myocardial infarction in rabbit

Biography:

Ali Ziaie Kia has completed his DVM degree from Faculty of Veterinary Medicine, Islamic Azad university, Iran in 2017. He is an assistant professor at Islamic Azad University, Iran. He is interested in small animal surgery and works as major clinician in Pulse Pet Clinic in Tehran, Iran.

Abstract:

Objective: Evaluation of the method and outcomes of experimental myocardial infarction in rabbit as an animal model for human and veterinary studies design: Experimental procedure case review study.

Animals: Six male New Zealand rabbit (body weight 2.3 kg) were used in this study.

Methods: Left lateral thoracotomy was performed in all cases. The LAD was ligated and gross changes were recorded. Post-operative echocardiography and measurement of blood level troponin was performed in all rabbits. All cases were kept under similar condition for one month. Before euthanasia a final echocardiography was performed. All cases were euthanized by standard methods and their heart completely harvested. Measurement of infarct size by planimetry and by the use of image software was done. All hearts were submitted for histopathologic evaluation and electronic microscopic studies. An indepth study of all data was performed.

Results: Histopathologic and gross myocardial changes in all cases were report. Echocardiographic changes were recorded at two distinct times; exactly after surgery and one month later before euthanasia. All echocardiographic measurements were done in both series of echocardiography.

Conclusion and clinical relevance: A thorough evaluation and study of histopathologic and echocardiographic changes of experimental myocardial infarction was performed and a detail explanation of procedure and surgical techniques was done.